Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Liauw, Winston ^a,b   Segelov, Eva ^a,d   Lih, Anna ^c   Dunleavy, Ruth ^a   Links, Matthew ^b,d   Ward, Robyn ^a,d  

^a ST VINCENT S HOSPITAL   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID; IMIDAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; BONE DISEASE; BONE SCINTISCANNING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SCREENING; DRUG UTILIZATION; FEMALE; FREQUENCY ANALYSIS; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; NEPHROTOXICITY; ORTHOPEDIC SURGERY; PRACTICE GUIDELINE; RADIOTHERAPY; RETROSPECTIVE STUDY; SPINAL CORD COMPRESSION; VERTEBRA FRACTURE; AGED; BONE TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); DISEASE COURSE; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; PATHOLOGY; TIME; TREATMENT OUTCOME;

AGED; BONE DISEASES; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DISEASE PROGRESSION; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 26844449429     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-89     Document Type: Article

References (21)

1. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996, 335:1785-1791.
2. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998, 16:2038-2044.
3. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999, 17:846-854.
4. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, doubleblind, comparative trial. Cancer J 2001, 7:377-387.
5. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98:1735-1744.
6. Rosen LS, Gordon DH, Dugan WJ, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004, 100:36-43.
7. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005, 23:3314-3321.
8. Pavlakis N, Stockler M: Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2002:CD003474.
9. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057.
10. Verma S, Kerr-Cresswell D, Dranitsaris G, Charbonneau F, Trudeau M, Yogendran G, Cesta AM, Clemons M: Bisphosphonate use for the management of breast cancer patients with bone metastases: A survey of Canadian Medical Oncologists. Support Care Cancer 2004, 12:852-858.
11. Hillner BE, Weeks JC, Desch CE, Smith TJ: Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000, 18:72-79.
12. Body JJ: Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 2003, 97:859-865.
13. Clemons M, Enright K, Cesta A, Charbonneau F, Chow E, Warr D, Kee-Cresswell D, Chang J, Yogendran G, Trudeau M, De Angelis C, Cottrell W, Dranitsaris G: Do physicians follow systemic treatment and funding policy guidelines? Can J Clin Pharmacol 2004, 11:e168-78.
14. Enright K, Clemons M, Chow E: Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience. Support Care Cancer 2004, 12:48-52.
15. Coleman R, Rubens R: The clinical course of bone metastases from breast cancer. British Journal of Cancer 1987, 55:61-66.
16. Coleman RE: Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
17. Plunkett TA, Smith P, Rubens RD: Risk of complications from bone metastases in breast cancer. implications for management. Eur J Cancer 2000, 36:476-482.
18. Cook RJ, Lawless JF: Interim monitoring of longitudinal comparative studies with recurrent event responses. Biometrics 1996, 52:1311-1323.
19. Ghosh D, Lin DY: Nonparametric analysis of recurrent events and death. Biometrics 2000, 56:554-562.
20. Major PP, Cook R: Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002, 25:S10-8.
21. Coleman RE: Bisphosphonates: clinical experience. Oncologist 2004, 9:14-27.